Guardian

‘Unprecedented’ global effort gives new name to polycystic ovary syndrome – and new hope to millions of women

ABC Australia

Polycystic ovary syndrome renamed polyendocrine metabolic ovarian syndrome

India Today

PCOS renamed PMOS: Why this common hormone disorder got a new name

KURIER

PCOS wird umbenannt: Zysten sind nicht das eigentliche Problem

Polycystic ovary syndrome (PCOS) has a new name

The Lancet

Fulltext

University of Colorado Anschutz

Global Experts Establish New Name for PCOS to Reflect Multisystem Disease

Metaculus

0.25 Births Per Woman Globally by 2046

JAMA Network

2848540

Polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) following a global consensus study published in The Lancet and announced at the European Congress of Endocrinology in Prague.

Polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) following a global consensus study published in The Lancet and announced at the European Congress of Endocrinology in Prague.

The renaming effort, led by Australian endocrinologist Helena Teede of Monash University's Centre for Health Research & Implementation, took 14 years and drew more than 22,000 survey responses from patients and health professionals across six continents.

The renaming effort, led by Australian endocrinologist Helena Teede of Monash University's Centre for Health Research & Implementation, took 14 years and drew more than 22,000 survey responses from patients and health professionals across six continents.

A study of more than 1,200 Finnish women, published in JAMA Internal Medicine, found that women with PCOS did not have a higher rate of abnormal ovarian cysts than those without the condition, undermining a core implication of the former name.

A study of more than 1,200 Finnish women, published in JAMA Internal Medicine, found that women with PCOS did not have a higher rate of abnormal ovarian cysts than those without the condition, undermining a core implication of the former name.

PMOS affects approximately one in eight women — around 170 million people globally — and is associated with irregular periods, elevated androgen levels, insulin resistance, type 2 diabetes, cardiovascular disease and mental health conditions.

PMOS affects approximately one in eight women — around 170 million people globally — and is associated with irregular periods, elevated androgen levels, insulin resistance, type 2 diabetes, cardiovascular disease and mental health conditions.

The new name is intended to reflect the condition's hormonal and metabolic complexity, with "polyendocrine" referring to multiple hormone systems, "metabolic" addressing blood sugar and cardiovascular risks, and "ovarian" acknowledging reproductive impacts.

The new name is intended to reflect the condition's hormonal and metabolic complexity, with "polyendocrine" referring to multiple hormone systems, "metabolic" addressing blood sugar and cardiovascular risks, and "ovarian" acknowledging reproductive impacts.

PCOS Challenge, the largest PCOS patient advocacy organization globally, said the renaming process "did not meet the evidentiary, ethical, and implementation standard required," arguing that a name change alone does not address training gaps, reimbursement structures or access to care.

PR Newswire

PCOS Challenge, the largest PCOS patient advocacy organization globally, said the renaming process "did not meet the evidentiary, ethical, and implementation standard required," arguing that a name change alone does not address training gaps, reimbursement structures or access to care.

PCOS Officially Renamed PMOS After 14-Year Study

PCOS Officially Renamed PMOS After 14-Year Study

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

PCOS Officially Renamed PMOS After 14-Year Study

PCOS Officially Renamed PMOS After 14-Year Study

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters